electroCore Engages FNK IR to Execute Expanded Investor Relations Program
electroCore, a bioelectronic medicine and wellness company, has engaged FNK IR to expand its investor relations program. The company has reported seven consecutive quarters of record revenue and a five-year CAGR of 69%. CEO Dan Goldberger cited strong financial performance, high gross margins, and improving operating leverage as reasons for enhancing their investor relations efforts.
Rob Fink, Managing Partner of FNK IR, highlighted electroCore's rapid growth, efficient operations, and strong sales channels. The engagement aims to broaden awareness of electroCore among relevant investors and drive sustainable shareholder value. The company expects to generate positive cash flow early next year.
electroCore, un'azienda di medicina bioelettronica e benessere, ha coinvolto FNK IR per espandere il proprio programma di relazioni con gli investitori. L'azienda ha registrato sette trimestri consecutivi di ricavi record e un CAGR di cinque anni del 69%. Il CEO Dan Goldberger ha citato una solida performance finanziaria, alte marginalità lorde e un miglioramento della leva operativa come motivi per potenziare le proprie iniziative nelle relazioni con gli investitori.
Rob Fink, Managing Partner di FNK IR, ha sottolineato la crescita rapida, le operazioni efficienti e i forti canali di vendita di electroCore. L'obiettivo dell'incarico è ampliare la consapevolezza di electroCore tra gli investitori pertinenti e guidare un valore sostenibile per gli azionisti. L'azienda prevede di generare un flusso di cassa positivo all'inizio del prossimo anno.
electroCore, una empresa de medicina bioelectrónica y bienestar, ha contratado a FNK IR para expandir su programa de relaciones con inversores. La empresa ha reportado siete trimestres consecutivos de ingresos récord y un CAGR de cinco años del 69%. El CEO Dan Goldberger citó un sólido desempeño financiero, altos márgenes brutos y una mejora en la palanca operativa como razones para fortalecer sus esfuerzos en relaciones con inversores.
Rob Fink, socio gerente de FNK IR, destacó el crecimiento rápido, las operaciones eficientes y los fuertes canales de ventas de electroCore. El compromiso tiene como objetivo ampliar la conciencia sobre electroCore entre inversionistas relevantes y impulsar un valor sostenible para los accionistas. La empresa espera generar un flujo de caja positivo a principios del próximo año.
electroCore는 생물전자 의학 및 웰빙 회사로, FNK IR을 고용하여 투자자 관계 프로그램을 확장하고 있습니다. 회사는 7분기 연속으로 기록적인 수익을 보고했으며, 5년 동안의 CAGR이 69%에 달하고 있습니다. CEO Dan Goldberger는 강력한 재무 성과, 높은 총 마진, 개선되는 운영 레버리지를 투자자 관계 노력을 강화하는 이유로 들었습니다.
FNK IR의 관리 파트너 Rob Fink은 electroCore의 빠른 성장, 효율적인 운영, 강력한 판매 채널을 강조했습니다. 이번 협업의 목표는 관련 투자자들에게 electroCore를 알리는 것과 지속 가능한 주주 가치를 창출하는 것입니다. 회사는 내년 초에 긍정적인 현금 흐름을 생성할 것으로 기대하고 있습니다.
electroCore, une entreprise de médecine bioélectronique et de bien-être, a engagé FNK IR pour élargir son programme de relations avec les investisseurs. L'entreprise a annoncé sept trimestres consécutifs de revenus record et un CAGR de 69% sur cinq ans. Le PDG Dan Goldberger a cité de solides performances financières, de fortes marges brutes, et une amélioration de l'effet de levier opérationnel comme raisons d'intensifier leurs efforts en matière de relations avec les investisseurs.
Rob Fink, associé directeur de FNK IR, a souligné la croissance rapide, l'efficacité opérationnelle, et les forts canaux de vente d'electroCore. L'engagement vise à sensibiliser les investisseurs concernés à electroCore et à générer une valeur durable pour les actionnaires. L'entreprise s'attend à générer un flux de trésorerie positif au début de l'année prochaine.
electroCore, ein Unternehmen für bioelektronische Medizin und Wellness, hat FNK IR beauftragt, sein Investor-Relations-Programm zu erweitern. Das Unternehmen hat sieben aufeinanderfolgende Quartale mit Rekordumsätzen und ein CAGR von 69% über fünf Jahre gemeldet. CEO Dan Goldberger führte starke finanzielle Ergebnisse, hohe Bruttomargen und verbesserte Betriebseffizienz als Gründe für die Intensivierung ihrer Investor-Relations-Bemühungen an.
Rob Fink, Managing Partner von FNK IR, hob das schnelle Wachstum, die effizienten Abläufe und die starken Vertriebskanäle von electroCore hervor. Das Ziel des Engagements besteht darin, das Bewusstsein für electroCore bei relevanten Investoren zu erhöhen und nachhaltigen Aktionärswert zu schaffen. Das Unternehmen erwartet, Anfang nächsten Jahres einen positiven Cashflow zu generieren.
- Seven consecutive quarters of record revenue
- Five-year CAGR of 69%
- Consistently high gross margins
- Improving operating leverage
- Expected positive cash flow early next year
- Strong sales channels and accelerating adoption
- None.
ROCKAWAY, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has engaged FNK IR, an institutionally focused investor relations consulting firm, to develop and deploy an expanded outreach and communications program.
Dan Goldberger, Chief Executive Officer of electroCore, commented, “electroCore has demonstrated strong financial performance, delivering seven consecutive quarters of record revenue and driving of five-year CAGR of
Rob Fink, Managing Partner of FNK IR, commented, “electroCore is growing rapidly and operating efficiently. With a proven management team, consistent margins, strong sales channels and accelerating adoption within a large and growing market, we believe electroCore’s investment proposition is compelling. Our work will focus on broadening awareness of electroCore to expand the company’s audience of relevant investors as management advances efforts that will unlock and drive sustainable shareholder value.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About FNK IR
FNK IR is a highly strategic, investor-minded investor relations consulting firm that helps smaller and emerging public companies navigate the capital markets, enhancing awareness, creditability and ultimately valuation. FNK IR’s exclusively senior team has decades of experience investing in, partnering with, and working at public companies. To learn more, please visit www.fnkir.com
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the implications of the retention of Fink IR, broadening of investor audience, electroCore's business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally in particular to accelerate training, and other statements that are not historical in nature, particularly those using terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize nVNS products, competition in the industry in which electroCore operates and general market conditions. The results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies, clinical trials, or commercial success. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
Rob Fink
FNK IR
ecor@fnkir.com
(646) 809-4048
FAQ
What is electroCore's recent financial performance according to the press release?
Why did electroCore (ECOR) engage FNK IR?
When does electroCore (ECOR) expect to generate positive cash flow?
What are the key strengths of electroCore (ECOR) highlighted by FNK IR?
